Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-30

Study Completion Date

2022-11-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This exploratory, prospective, controlled, multisite, open label, randomized clinical trial with two treatment arms aims to compare favipiravir, a new treatment candidate for Lassa fever (LF), with the current standard of care, ribavirin.

The primary endpoints of this research are (1) the description of classical pharmacokinetic parameters of favipiravir in comparison with ribavirin standard treatment in patients suffering from LF and (2) the safety and tolerability of both study drugs in the investigated regimens.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever

NCT03889106

Lassa Fever

TERMINATED

Favipiravir in High-risk COVID-19 Patients

NCT04818320

Covid19

COMPLETED PHASE3

Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever

NCT02483260

Viral Hemorrhagic Fever

ENROLLING_BY_INVITATION NA

Efficacy of Favipiravir Against Severe Ebola Virus Disease

NCT02662855

Ebola Virus Disease

COMPLETED PHASE2

Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh

NCT04402203

COVID-19 Favipiravir (Favipira)

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The currently used antiviral for the treatment of LF, which is also recommended by the World Health Organization (WHO) and the Nigeria Center for Disease Control, is ribavirin. However, evidence for ribavirin efficacy in LF patients adds up to the results of a single study with serious limitations. A promising new treatment candidate that showed efficacy against LF in preclinical studies is Favipiravir. It has further been evaluated for the treatment of Ebola Virus disease during the West-African Ebola outbreak and is approved for treatment of pandemic influenza virus infections in Japan.

The study will be conducted at two study sites in Nigeria: the Irrua Specialist Teaching Hospital (ISTH) and the Federal Medical Center of Owo (FMCO). Lassa fever patients of 18 years and older with LF confirmed by reverse-transcription polymerase chain reaction (RT-PCR) hospitalized at either ISTH or FMCO will be asked to participate in this study. A total of 40 evaluable participants will be randomized to two treatment arms (20 participants per arm): intravenous ribavirin standard of care treatment (Irrua regimen), oral favipiravir. Patients will be included in the study after giving written informed consent and if all inclusion criteria and no exclusion criteria are met. Multiple blood draws with the purpose of virologic, serologic and immunological analyses, hematological and biochemical analyses as well as pharmacokinetic analyses will be performed throughout the study duration of ten days. Adverse events (AEs), serious adverse events (SAEs) and pregnancy will be captured, monitored and followed-up. A medical monitor will be available for study investigators to assist with any clinical and safety related questions. An external data safety monitoring board (DSMB) will conduct periodic safety reviews.

Data will be captured on source documents and electronic case report forms (eCRFs). Informed consent forms will be stored in a lockable cabinet. Participants data will only be linked to the unique identifier to ensure pseudonymity.

Statistical analysis of study endpoints and pharmacokinetic parameters will be performed descriptively. Missing data will be treated as such, no imputation will be applied.

The study will be conducted in compliance with the protocol, the Declaration of Helsinki, the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guideline and the Nigerian National Code for Health Research Ethics, in particular concerning the submission to the ethics committees and the protection of personal data as well as other national and regulatory requirements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lassa Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Exploratory, prospective, controlled, multisite, open label, randomized clinical trial with two arms

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravenous ribavirin

standard treatment: Irrua regimen

* 100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day)
* 25 mg/kg days 2-7
* 12.5 mg/kg days 8-10

Group Type ACTIVE_COMPARATOR

Ribavirin iv

Intervention Type DRUG

100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10

Oral favipiravir

Oral favipiravir

* Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16)
* Day 2-10 1200mg twice daily (BD)

Group Type EXPERIMENTAL

Favipiravir

Intervention Type DRUG

Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ribavirin iv

100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10

Intervention Type DRUG

Favipiravir

Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Irrua regimen Avigan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* LF confirmed by RT-PCR (reverse-transcription polymerase chain reaction)
* Written informed consent

Exclusion Criteria

* Inability to give consent (e.g. unconscious patients/ cognitively impaired patients)
* Pregnancy/lactation (evidenced by negative urine pregnancy test in women of child-bearing potential)
* Women who plan to get pregnant within the upcoming 6 months
* Severe malnutrition (BMI\<16)
* Known intolerance to ribavirin or favipiravir
* History of hemoglobinopathies (i.e., sickle-cell anaemia or thalassemia major) and/or haemophilia
* Organ failure as evidenced by:

* Creatinine ≥ 3x upper limit of normal (ULN)
* Aspartate aminotransferase (AST/GOT) \> 150 IU/l
* Alert, confusion, voice, pain, unresponsive (ACVPU) score = V or P or U (corresponds to Glasgow Coma Scale (GCS) ≤ 12)
* Severe central nervous system features (e.g. seizures, restlessness, confusion and coma)
* O2 Saturation \< 90%
* Hematocrit \<30 %
* Severe anaemia requiring blood transfusion
* Inability to take oral drug (e.g. encephalopathy, severe vomiting)
* Patients who already received ribavirin or favipiravir within the preceding 7 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No